

#### Director/PDMR Shareholding - transfer of shares to SIPP

Following the purchase and sale transactions, there is no change to Mr Lefort's beneficial holding (including that of his spouse) and the total interest in the Company remains the same at 1,451,621 Common Shares, representing approximately 1.36% of the Company's issued share capital.

**END**

## AOTI, INC.

+44 (0)20 3727 1000  
[ir@aotinc.net](mailto:ir@aotinc.net)

Dr. Christopher Golden, James Steel

+44 (0)20 7418 8900

Ben Atwell, Simon Conway,  
Natalie Garland-Collins, Alex Davis

+44 (0)20 3727 1000  
AOTI@fitconsulting.com

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO<sub>2</sub><sup>®</sup>) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO<sub>2</sub><sup>®</sup> therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO<sub>2</sub><sup>®</sup> therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see [www.aotinc.net](http://www.aotinc.net)

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	1. Mr Douglas Lefort 2. Mrs Gillian Lefort
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	1. Non-executive Chairman 2. PCA of Douglas Lefort
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	AOTI Inc.
b)	EPA	01-00007000-1007A/EP/0007

D)	LEI	Z1360U2GUND51WIRN007												
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted													
a)	Description of the financial instrument, type of instrument	Common shares of 0.00001 each												
	Identification code	ISIN: US03690C1027												
b)	Nature of the transaction	1. Purchase of Common Shares into Mr Lefort's SIPP on 20 March 2025 2. Sale of Common Shares by Mr Lefort on 20 March 2025 3. Purchase of Common Shares into Mrs Lefort's SIPP on 25 March 2025 4. Sale of Common Shares by Mrs Lefort on 25 March 2025												
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>1. 102.5p</td><td>194,117</td></tr><tr><td>2. 102.5p</td><td>194,117</td></tr><tr><td>3. 95.0p</td><td>167,336</td></tr><tr><td>4. 95.0p</td><td>167,336</td></tr></table>	Price(s)	Volume(s)	1. 102.5p	194,117	2. 102.5p	194,117	3. 95.0p	167,336	4. 95.0p	167,336		
Price(s)	Volume(s)													
1. 102.5p	194,117													
2. 102.5p	194,117													
3. 95.0p	167,336													
4. 95.0p	167,336													
d)	Aggregated information													
	- Aggregated volume	361,453												
	- Price	99.03p												
e)	Date of the transaction	1, 2 - 20 March 2025 3,4 - 25 March 2025												
f)	Place of the transaction	London Stock Exchange												

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBRGDXLUDDGUU